Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorBRANGIER, A.
dc.contributor.authorFERLAND, G.
dc.contributor.authorROLLAND, Y.
dc.contributor.authorGAUTIER, J.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorFEART-COURET, Catherine
ORCID: 0000-0002-7959-1610
IDREF: 08195848X
dc.contributor.authorANNWEILER, C.
dc.date.accessioned2020-10-27T08:01:58Z
dc.date.available2020-10-27T08:01:58Z
dc.date.issued2018-05-24
dc.identifier.issn2072-6643 (Electronic) 2072-6643 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/11485
dc.description.abstractEnVitamin K participates in brain physiology. This study aimed to determine whether using vitamin K antagonists (VKAs), which interfere with the vitamin K cycle, were (i) cross-sectionally associated with altered cognitive performance, and (ii) independent predictors of cognitive changes in older adults over 24 months. Information was collected on the use of VKAs (i.e., warfarin, acenocoumarol, and fluindione) among 378 geriatric outpatients (mean, 82.3 +/- 5.6 years; 60.1% female). Global cognitive performance and executive functions were assessed with Mini-Mental State Examination (MMSE) and Frontal Assessment Battery (FAB) scores, respectively, at baseline and after 12 and 24 months of follow-up. Age, gender, body mass index, mean arterial pressure, disability, gait speed, comorbidities, atrial fibrillation, stroke, carotid artery stenosis, leukoaraiosis grade on computed tomography (CT) scan, psychoactive drugs, antidementia drugs, blood-thinning drugs (i.e., anticoagulants other than VKAs, antiplatelet medications), serum creatinine levels, and vitamin B12 concentrations were considered as potential confounders. Using VKAs was associated with lower (i.e., worse) FAB score at baseline (adjusted beta = -2.1, p = 0.026), and with a decrease in FAB score after 24 months (adjusted beta = -203.6%, p = 0.010), but not after 12 months (p = 0.659). Using VKAs was not associated with any change in MMSE score at baseline (p = 0.655), after 12 months (p = 0.603), or after 24 months (p = 0.201). In conclusion, we found more severe executive dysfunction at baseline and incident executive decline over 24 months among geriatric patients using VKAs, when compared with their counterparts.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enLEHA
dc.title.enVitamin K Antagonists and Cognitive Decline in Older Adults: A 24-Month Follow-Up
dc.title.alternativeNutrientsen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.3390/nu10060666en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed29794977en_US
bordeaux.journalNutrientsen_US
bordeaux.volume10en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue6en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamLEHA_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Nutrients&rft.date=2018-05-24&rft.volume=10&rft.issue=6&rft.eissn=2072-6643%20(Electronic)%202072-6643%20(Linking)&rft.issn=2072-6643%20(Electronic)%202072-6643%20(Linking)&rft.au=BRANGIER,%20A.&FERLAND,%20G.&ROLLAND,%20Y.&GAUTIER,%20J.&FEART-COURET,%20Catherine&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée